Burning Rock Biotech
Burning Rock Biotech, a leading player in the biotechnology sector, is headquartered in China and operates extensively across Asia and beyond. Founded in 2014, the company has rapidly established itself as a pioneer in precision oncology, focusing on innovative genomic testing solutions that enhance cancer diagnosis and treatment. The firm’s core offerings include comprehensive genomic profiling and liquid biopsy services, which are distinguished by their accuracy and efficiency. Burning Rock Biotech's commitment to advancing personalised medicine has positioned it as a key contributor to the global fight against cancer, earning recognition for its cutting-edge technology and robust research capabilities. With a strong market presence and notable achievements in regulatory approvals, Burning Rock Biotech continues to drive advancements in the field, making significant strides in improving patient outcomes through tailored therapeutic strategies.
DitchCarbon Score
How does Burning Rock Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Burning Rock Biotech's score of 36 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Burning Rock Biotech's reported carbon emissions
As of the latest available data, Burning Rock Biotech, headquartered in China, has not reported any specific carbon emissions figures. However, the company has made significant climate commitments through the Science Based Targets initiative (SBTi). Burning Rock Biotech has set near-term targets to reduce absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2022 as the base year. Additionally, the company aims to increase its annual active sourcing of renewable electricity from 0% in 2022 to 100% by 2030. For Scope 3 emissions, a reduction target of 25% by 2030 has also been established. In the long term, Burning Rock Biotech is committed to achieving net-zero GHG emissions across its entire value chain by 2050. This includes a substantial reduction of 90% in both Scope 1 and Scope 2 emissions by 2050, as well as a similar 90% reduction in Scope 3 emissions by the same year. These targets reflect the company's alignment with global climate goals and its commitment to sustainable practices within the professional services sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Burning Rock Biotech is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
